Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2025-06-23), Genmab AS's Intrinsic Value: Projected FCF is kr1,557.77. The stock price of Genmab AS is kr1378.50. Therefore, Genmab AS's Price-to-Intrinsic-Value-Projected-FCF of today is 0.9.
The historical rank and industry rank for Genmab AS's Intrinsic Value: Projected FCF or its related term are showing as below:
CHIX:GMABc'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.86 Med: 4.43 Max: 35.77
Current: 0.88
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Genmab AS was 35.77. The lowest was 0.86. And the median was 4.43.
CHIX:GMABc's Price-to-Projected-FCF is ranked better than 82.17% of 230
companies
in the Biotechnology industry
Industry Median: 2.16
vs CHIX:GMABc: 0.88
Genmab AS Intrinsic Value: Projected FCF Historical Data
The historical data trend for Genmab AS's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Genmab AS's Intrinsic Value: Projected FCF
For the Biotechnology subindustry, Genmab AS's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS's Price-to-Projected-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Genmab AS's Price-to-Projected-FCF falls into.
Genmab AS Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS (CHIX:GMABc) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Genmab AS's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
1378.50
/
1556.069632382
=
0.89
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS Intrinsic Value: Projected FCF Related Terms
Thank you for viewing the detailed overview of Genmab AS's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHIX:GMABC has been successfully added to your 